Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600129'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -32.47 Med: 6.06 Max: 163.94
Current: 5.42
During the past 13 years, Chongqing Taiji Industry (Group) Co's highest Return-on-Tangible-Equity was 163.94%. The lowest was -32.47%. And the median was 6.06%.
SHSE:600129's Return-on-Tangible-Equity is ranked worse than 57.6% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs SHSE:600129: 5.42
Chongqing Taiji Industry (Group) Co (SHSE:600129) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chongqing Taiji Industry (Group) Co Return-on-Tangible-Equity Related Terms
Chongqing Taiji Industry (Group) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co Return-on-Tangible-Equity Chart
SHSE:600129 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Taiji Industry (Group) Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.69% mean?
Chongqing Taiji Industry (Group) Co (SHSE:600129) has a Return-on-Tangible-Equity of 12.69% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. This is 109% above median its historical median of 6.06. According to the industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #519 out of 901 companies in the Drug Manufacturers industry, placing it in the top 57.6%.
Is Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity too high?
Chongqing Taiji Industry (Group) Co's current Return-on-Tangible-Equity of 12.69% is 109% above median its 10-year median of 6.06. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Chongqing Taiji Industry (Group) Co's value of 12.69% is 60.6% above this industry median. Based on the distribution chart, Chongqing Taiji Industry (Group) Co ranks #519 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chongqing Taiji Industry (Group) Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Taiji Industry (Group) Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #519 out of 901 companies for Return-on-Tangible-Equity. This places Chongqing Taiji Industry (Group) Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Chongqing Taiji Industry (Group) Co's value of 12.69% is 60.6% above this benchmark. While the company's 10-year median is 6.06 vs. the industry median of 7.90, Chongqing Taiji Industry (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Taiji Industry (Group) Co's current Return-on-Tangible-Equity of 12.69% is 60.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Taiji Industry (Group) Co's current Return-on-Tangible-Equity is 12.69%, which is 109% above median its own 10-year median of 6.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Taiji Industry (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co (SHSE:600129) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.84, compared to a current price of ¥14.96 — trading 28.2% below its estimated fair value. The current Return-on-Tangible-Equity is 12.69%, which is 109% above median its 10-year median of 6.06 and 60.6% above the Drug Manufacturers industry median of 7.90. Chongqing Taiji Industry (Group) Co's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chongqing Taiji Industry (Group) Co (SHSE:600129), the current Return-on-Tangible-Equity is 12.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Taiji Industry (Group) Co (SHSE:600129) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co stock appears to be undervalued.
The current stock price of ¥14.96 is trading 28.2% below its estimated GF Value™ of ¥20.84.
GuruFocus considers Chongqing Taiji Industry (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600129:
Return-on-Tangible-Equity: 12.69% (109% above median its 10-year median of 6.06)
GF Value™: ¥20.84 vs. price of ¥14.96 (28.2% below fair value)
Industry Position: 60.6% above the Drug Manufacturers median (#519 of 901)
No single metric tells the full story. See the SHSE:600129 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chongqing Taiji Industry (Group) Co Business Description
Chongqing Taiji Industry (Group) Co Ltd is a China-based company engaged in the production and sales of Chinese and Western medicines. It is also engaged in the cultivation of medicinal herbs. Its products mainly include capsules, syrup, oral liquid, lyophilized series, tablets, infusion series, and injections. The company mainly conducts its business in domestic and overseas markets.
62GF Score
Get the complete analysis for SHSE:600129
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600129 has been successfully added to your 
